CIK 0001821586 · Large accelerated filer
MoonLake Immunotherapeutics
Sign in to watch- Ticker
- MLTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Cayman Islands
- Entity type
- operating
- Phone
- 41 41 510 8022
- Business address
- DORFSTRASSE 29, ZUG, Switzerland, 6300
- Former names
- Helix Acquisition Corp
- 4 Conversion Chief Scientific Officer acquired 111,949 shares (conversion)
- 4 Open-market sale Director sold 2,000,000 shares at $50.00 ($100,003,200)
- 4 Open-market sale Director sold 171,000 shares at $53.72 ($9,186,120)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale Chief Executive Officer sold 123,615 shares at an average $55.03 ($6,803,044)
- 4 Planned sale Chief Scientific Officer sold 118,922 shares at $55.00 ($6,540,710)
- 4 Planned sale Chief Executive Officer sold 1,125 shares at $55.27 ($62,179)
- 4 Planned sale Chief Scientific Officer sold 21,078 shares at an average $57.33 ($1,208,418)
- 4 Planned sale Chief Executive Officer sold 60,000 shares at an average $59.26 ($3,555,400)
- 4 Planned sale Chief Scientific Officer sold 60,000 shares at an average $60.91 ($3,654,800)
- 4 Planned sale Chief Financial Officer sold 100,000 shares at an average $59.17 ($5,917,368)
- 4 Open-market buy 10% owner bought 58,839 shares at $59.90 ($3,524,297)
- 4 Open-market buy 10% owner bought 293,212 shares at an average $57.30 ($16,800,343)
- 4 Conversion Director acquired 342,980 shares (conversion)
- 4 Conversion Chief Financial Officer acquired 62,972 shares (conversion)
Page 3 of 5 · 97 filings